Founders:
Min-Han Tan
Presence:
Singapore
Milestones:

Founded in 2021
Founded in 2021
Founded in 2021
Founded in 2022
Founded in 2022
Founded in 2016
Founded in 2021
Invested in 2020
Invested in 2022
Founded in 2017
Founded in 2021
Founded in 2021
Invested in 2021
Founded in 2018
Invested in 2014 Led Series A
Invested in 2018
Invested in 2020
Invested in
Invested in 2021
Founded in 2010
Invested in 2019
Invested in 2016
Invested in 2017
Invested in 2014
Founded in 2002
Founded in 2008
Founded in 2014
Founded in 2007
Founded in 2020
Founded in 2012
Founded in 2018
Founded in 2013
Founded in 2006
Founded in 2017
Founded in 2016
Founded in 2015
Invested in 2015
Founded in 2011
Sector:
Healthtech
Back to Portfolio
Actively making cancer more detectable, faster.

Lucence has a proprietary sequencing technology was first invented in Singapore to enable non-invasive cancer treatment selection via ultrasensitive liquid biopsy. This technology has now been brought to the world stage via its flagship blood test, LiquidHALLMARK - with impressive milestones already reached.

This technology has also now been applied to a further breakthrough core product, LucenceINSIGHT. Launched in Asia in 2023, it uses these liquid biopsies to detect cancer earlier, giving people a real chance to discover and treat the disease. LucenceINSIGHT will help deliver better outcomes on an individual patient level, and lower the rate of avoidable cancer deaths. On a systemic level, it will help reduce the burdens of cancercare on health systems across the world, often confronting ageing populations.

next COMPANY